Welcome to our dedicated page for Fennec Pharmaceuticals SEC filings (Ticker: FENC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fennec Pharmaceuticals Inc. (FENC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other documents filed under its Exchange Act reporting obligations. Fennec is a specialty pharmaceutical company focused on PEDMARK®, a sodium thiosulfate injection indicated to reduce the risk of cisplatin-induced ototoxicity in certain pediatric cancer patients.
Recent Form 8-K filings describe material definitive agreements and financing activities, such as an underwriting agreement for an underwritten registered public offering of common shares and subscription agreements for a non-brokered offering of common shares in Canada. These filings outline key terms of the offerings, the number of shares issued, the public offering price and the use of proceeds.
Other 8-K reports detail a Waiver and Redemption Agreement with Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP, under which Fennec agreed to repurchase and redeem its remaining senior secured floating rate convertible notes. The company reports that, after completing this transaction, all payment obligations under the notes were satisfied in full, and related news releases are incorporated by reference in the filings.
On Stock Titan, these filings are updated as they are made available through EDGAR. AI-powered tools can help readers quickly identify the purpose of each filing, such as equity offerings, debt redemptions or other corporate events, and understand how they relate to Fennec’s ongoing commercialization of PEDMARK® and its capital structure. Users can also track exhibits referenced in the 8-Ks, including underwriting agreements, subscription agreements, legal opinions and press releases.
FENNEC PHARMACEUTICALS INC. Chief Executive Officer Jeffrey S. Hackman acquired common shares through an equity award vesting. On settlement of performance share units that vested on February 18, 2026, he received 13,710 common shares at no stated exercise price. Following this non-cash derivative exercise, his direct ownership increased to 28,710 common shares.
FENNEC PHARMACEUTICALS INC. chief financial officer Robert Andrade reported equity award activity involving both stock options and performance share units. On February 18, 2026, he exercised stock options for 2,450 shares at $4.08 per share, resulting in 215,108 common shares held directly after that transaction. He also acquired 27,285 additional common shares at no exercise price through the settlement of PSUs that vested on the same date, bringing his directly held common shares to 242,393. Following these transactions, his directly held stock options totaled 814,117.
Sonic Fund II, L.P. and related parties report an 8.2% stake in Fennec Pharmaceuticals Inc. As of December 31, 2025, they may be deemed to beneficially own 2,799,959 common shares.
The shares are held directly by Sonic Fund II, L.P., with Sonic GP LLC as its general partner and Lawrence Kam as managing member. Mr. Kam also directly holds shares over which he has sole voting and dispositive power. The filers certify the holdings are not for the purpose of changing or influencing control of Fennec Pharmaceuticals.
Rosalind Advisors Inc. and related investors report a significant passive stake in Fennec Pharmaceuticals Inc. common shares. As of the event date of December 31, 2025, they report beneficial ownership ranging from 9.3% to 9.8% of the company’s common shares, based on 28,116,829 shares outstanding as of November 10, 2025.
Rosalind Master Fund L.P. reports beneficial ownership of 2,613,508 shares, or 9.3% of the class. Rosalind Advisors Inc., as investment adviser, reports 2,746,840 shares, or 9.8%. Portfolio managers Steven Salamon and Gilad Aharon each report beneficial ownership of 2,680,174 shares, or 9.5%, including 66,666 shares over which each has sole voting and dispositive power.
The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control of Fennec Pharmaceuticals.
Fennec Pharmaceuticals director Rosty Raykov reported insider transactions involving stock options and common shares. On February 2, 2026, he exercised 15,598 stock options at an exercise price of $2.45 per option under a Rule 10b5-1 trading plan adopted on September 19, 2025, receiving the same number of common shares.
On the same date, he sold 10,349 common shares at $7.76 per share to satisfy tax obligations related to the option exercise. After these transactions, he directly owned 98,477 common shares and 1,602,988 stock options in Fennec Pharmaceuticals.
An insider associated with FENC has filed a notice of intent to sell 10,349 common shares through Morgan Stanley Smith Barney LLC on or around 02/02/2026, with the shares to be sold on NASDAQ.
The shares were acquired the same day via a stock option exercise paid in cash. Over the prior three months, the same seller, Rostislav Raykov, sold additional blocks of common stock totaling 30,312 shares for gross proceeds of about $235,000. The issuer had 28,116,829 shares outstanding when this notice was prepared.
Fennec Pharmaceuticals director Rosty Raykov reported a routine equity change as 5,208 common shares were acquired on January 31, 2026 at a price of $0 per share. These shares were released from restrictions tied to awards originally granted on March 31, 2023 and May 16, 2024.
Following this release of previously awarded stock, Raykov directly beneficially owns 93,228 common shares of Fennec Pharmaceuticals. The filing reflects a non-cash change in ownership from restricted to freely releasable shares rather than an open-market purchase or sale.
Fennec Pharmaceuticals chief financial officer Robert Andrade reported an equity change in the company’s common shares. On January 31, 2026, he acquired 1,558 common shares at a price of $0 per share through the release of restrictions on previously awarded shares.
These shares were released from restriction from awards originally granted on March 31, 2023 and May 16, 2024. Following this vesting event, Andrade directly holds a total of 212,658 common shares of Fennec Pharmaceuticals.
Fennec Pharmaceuticals Inc. chief financial officer exercises stock options for 10,000 shares. On January 23, 2026, CFO Robert Andrade exercised stock options with a strike price of $2.45 per share, acquiring 10,000 common shares of Fennec Pharmaceuticals Inc. following an option contract that was scheduled to expire on July 5, 2026.
After this transaction, Andrade directly held 211,100 common shares of Fennec and still held 816,567 stock options with an exercise price of $2.45, according to the filing.
Fennec Pharmaceuticals Inc. reported an insider transaction by its Chief Financial Officer, Robert Andrade. On 01/15/2026, he exercised 10,000 stock options with an exercise price of $2.45 per share, acquiring 10,000 common shares.
Following the transaction, Andrade directly beneficially owned 201,100 common shares and held 826,567 stock options that remained outstanding. The shares were acquired through the exercise of an option contract with a strike price of $2.45 and an expiration date of July 5, 2026.